Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis

Current Atherosclerosis Reports

Volumn 7, Issue 1, 2005, Pages 63-70

  Folmes, Clifford D L ^a   Clanachan, Alexander S ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICHLOROACETIC ACID; DILTIAZEM; GLUCOSE; INSULIN; NICOTINIC ACID; POTASSIUM; RANOLAZINE; TRIMETAZIDINE;

ATHEROSCLEROSIS; BIOACCUMULATION; CLINICAL TRIAL; DRUG HALF LIFE; DRUG POTENTIATION; ENERGY BALANCE; ENERGY METABOLISM; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART MUSCLE ISCHEMIA; HEART WORK; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OXYGEN CONSUMPTION; REVIEW;

EID: 15444361805     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-005-0077-2     Document Type: Review

References (57)

1. Opie LH: Heart Physiology, from Cell to Circulation. Philadelphia: Lippincott-Raven; 1998.
2. Neely JR, Morgan HE: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974, 36:413-459.
3. King LM, Opie LH: Glucose and glycogen utilisation in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998, 180:3-26.
4. Sambandam N, Lopaschuk GD: AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res 2003, 42:238-256.
5. Lopaschuk GD, Belke DD, Gamble J, et al.: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994, 1213:263-276.
6. Stanley WC, Chandler MP: Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002, 7:115-130.
7. Bonen A, Luiken JJ, Glatz JF: Regulation of fatty acid transport and membrane transporters in health and disease. Mol Cell Biochem 2002, 239:181-192.
8. Takahashi S, Sakai J, Fujino T, et al.: The very low density lipoprotein (VLDL) receptor - a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol Cell Biochem 2003, 248:121-127.
9. Abel ED: Glucose transport in the heart. Front Biosci 2004, 9:201-215.
10. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
11. Liu B, Clanachan AS, Schulz R, Lopaschuk GD: Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996, 79:940-948.
12. Liu B, el Alaoui-Talibi Z, Clanachan AS, et al.: Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol 1996, 270(1 Pt 2):H72-H80.
13. Benzi RH, Lerch R: Dissociation between contractile function and oxidative metabolism in postischemic myocardium. Attenuation by ruthenium red administered during reperfusion. Circ Res 1992, 71:567-576.
14. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR: Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res 1990, 66: 46-553.
15. Saddik M, Lopaschuk GD: Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991, 266:8162-8170.
16. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994, 343: 55-158.
17. Lopaschuk GD, Collins-Nakai R, Olley PM, et al.: Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 1994, 128:61-67.
18. Kudo N, Barr AJ, Barr RL, et al.: High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995, 270:17513-17520.
19. Hardie DG: AMP-activated protein kinase: a master switch in glucose and lipid metabolism. Rev Endocr Metab Disord 2004, 5:119-125.
20. Dyck JR, Kudo N, Barr AJ, et al.: Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem 1999, 262:184-190.
21. Musi N, Goodyear LJ: AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 2003, 178: 37-345.
22. Marsin AS, Bertrand L, Rider MH, et al.: Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000, 10:1247-1255.
23. Karmazyn M: The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann N Y Acad Sci 1999, 874: 326-334.
24. Sterling D, Casey JR: Bicarbonate transport proteins. Biochem Cell Biol 2002, 80:483-497.
25. Karmazyn M, Moffat MP: Na+/H+ exchange and regulation of intracellular Ca2+. Cardiovasc Res 1993, 27:2079-2080.
26. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic anti-arrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993, 270: 589-1595.
27. Sodi-Pallares D, Ponce de LJ, Bisteni A, Medrano GA: Potassium, glucose, and insulin in myocardial infarction. Lancet 1969, 1:1315-1316.
28. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997, 96: 152-1156.
29. Diaz R, Paolasso EA, Piegas LS, et al.: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998, 98:2227-2234.
30. Rosenson RS: Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003, 171:87-96.
31. Brown WV. Review of clinical trials: proving the lipid hypothesis. Eur Heart J 1990, 11(Suppl H):15-20.
32. Datta S, Das DK, Engelman RM, et al.: Enhanced myocardial preservation by nicotinic acid, an antilipolytic compound: mechanism of action. Basic Res Cardiol 1989, 84:63-76.
33. Trueblood NA, Ramasamy R, Wang LF, Schaefer S: Niacin protects the isolated heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2000, 279:H764-H771.
34. Kantor PF, Lucien A, Kozak R, Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86: 80-588.
35. Lopaschuk GD, Barr R, Thomas PD, Dyck JR: Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003, 93:e33-e37.
36. d'Alche P, Clauser P, Morel M, Gauthier V: Assessment with potential mapping of the cardiac protective effect of a drug. Example of trimetazidine. J Pharmacol Methods 1991, 26:43-51.
37. Libersa C, Honore E, Adamantidis M, et al.: Antiischemic effect of trimetazidine: enzymatic and electric response in a model of in-vitro myocardial ischemia. Cardiovasc Drugs Ther 1990, 4(Suppl 4):808-809.
38. Boucher FR, Hearse DJ, Opie LH: Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol1994, 24:45-49.
39. El BH, Bernard M, Baetz D, et al.: Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000, 47:688-696.
40. Detry JM, Sellier P, Pennaforte S, et al.: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994, 37: 79-288.
41. la-Volta S, Maraglino G, la-Valentina P, et al.: Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990, 4(Suppl 4):853-859.
42. Levy S: Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 1995, 76:12B-16B.
43. Sellier P, Audouin P, Payen B, et al.: Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987, 33:205-207.
44. Sellier P, Audouin P, Payen B, et al.: Ergometric effects of a single administration of trimetazidine. Presse Med 1986, 15:1771-1774.
45. Kober G, Buck T, Sievert H, Vallbracht C: Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992, 13:1109-1115.
46. Clarke B, Wyatt KM, McCormack JG: Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996, 28: 41-350.
47. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996, 93:135-142.
48. McCormack JG, Baracos VE, Barr R, Lopaschuk GD: Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol 1996, 81:905-910.
49. Gralinski MR, Black SC, Kilgore KS, et al.: Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 1994, 28:1231-1237.
50. Schofield RS, Hill JA: The use of ranolazine in cardiovascular disease. Expert Opin Investig Drugs 2002, 11: 17-123.
51. Chaitman BR, Skettino SL, Parker JO, et al.: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
52. Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
53. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989, 38:1124-1244.
54. Lopaschuk GD, Wambolt RB, Barr RL: An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 1993, 264:135-144.
55. McVeigh JJ, Lopaschuk GD: Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990, 259(4 Pt 2):H1079-H1085.
56. Mjos OD, Miller NE, Riemersma RA, Oliver MF: Effects of dichloroacetate on myocardial substrate extraction, epicardiat ST-segment elevation, and ventricular blood flow following coronary occlusion in dogs. Cardiovasc Res 1976, 10:427-436.
57. Wargovich TJ, MacDonald RG, Hill JA, et al.: Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988, 61:65-70.